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Summary
 
The requirements for inducing downregulation of 
 
a
 
/
 
b
 
 T cell receptor (TCR) molecules on
naive major histocompatibility complex class I–restricted T cells was investigated with 2C
TCR transgenic mice and defined peptides as antigen. Confirming previous results, activation
of 2C T cells in response to specific peptides required CD8 expression on the responder cells
and was heavily dependent upon costimulation provided by either B7-1 or ICAM-1 on anti-
gen-presenting cells (APC). These stringent requirements did not apply to TCR downregula-
tion. Thus, TCR downregulation seemed to depend solely on TCR/peptide/interaction and
did not require either CD8 or B7-1 expression; ICAM-1 potentiated TCR downregulation,
but only with limiting doses of peptides. TCR downregulation was most prominent with high
affinity peptides and appeared to be neither obligatory nor sufficient for T cell activation. In
marked contrast to T cell activation, TCR downregulation was resistant to various metabolic
inhibitors. The biological significance of TCR downregulation is unclear, but could be a de-
vice for protecting T cells against excessive signaling.
 
S
 
timulation of T cells via the TCR/CD3 complex elicits
a complex signaling cascade which leads to cell activa-
tion, proliferation, and differentiation into effector cells (1, 2).
In certain situations, TCR ligation is associated with recep-
tor downregulation. This process is easily seen with anti-
TCR antibodies and reflects receptor endocytosis via clathrin-
coated pits followed by degradation in lysozomes (3–12).
TCR downregulation also occurs when T cells recognize spe-
cific antigen, i.e., peptides bound to MHC molecules ex-
pressed on APCs (3, 13, 14).
The biological significance of TCR downregulation is
still unclear. Recently, Lanzavecchia et al. have provided
impressive evidence that TCR downregulation is an essen-
tial feature of T cell activation (15, 16). These workers
view rapid internalization of the TCR after contact with
antigen on APCs as a device to enable a large number of
TCR molecules to make contact with a limited number of
antigenic epitopes on the APCs. This model of sequential
interaction of a series of TCRs with individual antigenic
epitopes follows from the authors’ finding that T cell stim-
ulation requires engagement of a considerable number of
surface TCR molecules, i.e., 
 
z
 
8,000/cell; this number is
reduced by about fivefold with APCs expressing B7 mole-
cules (16). The precise connection between TCR down-
regulation and T cell activation is unclear. One possibility
is that TCR internalization serves to focus TCR-associated
kinases in the vicinity of downstream substrates, thereby
promoting or facilitating intracellular signaling (17). An al-
ternative explanation for TCR downregulation is that in-
ternalization of the receptors limits prolonged contact with
antigen, and thereby reduces the possibility that the T cell
is tolerized or destroyed through excessive TCR signaling.
This notion raises the question of whether TCR downreg-
ulation is an invariable feature of T cell activation.
The existing data on TCR downregulation are based al-
most entirely on studies with T cell clones and/or with
anti-TCR antibody as a surrogate antigen. Hence, there is
a need to define the requirements for inducing TCR
downregulation on naive T cells in response to specific an-
tigen. We have examined this question with the aid of a
well-characterized TCR transgenic model and antigenic
peptides with known affinity for TCR and MHC mole-
cules.
 
Materials and Methods
 
Mice.
 
2C TCR transgenic mice were originally obtained
from Dr. D. Loh (Nippon Roche Research Center, Kamakura-shi,
Japan; reference 18) and were bred and maintained in the rodent
breeding colony at The Scripps Research Institute (La Jolla, CA).
B10.D2/nSnJ (H-2
 
d
 
) and B10.D2 (R103)/Eg mice (K
 
d
 
 I-A
 
d
 
 I-E
 
d
 
D
 
b
 
 L
 
2
 
) were purchased from The Jackson Laboratory (Bar Har-
bor, ME).
 
Media.
 
HBSS supplemented with 2.5% 
 
g
 
-globulin–free horse
serum (GIBCO BRL, Santa Clara, CA) was used for preparation
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of single cell suspensions (19). For proliferation assays, RPMI 1640
was supplemented with 10% fetal calf serum (Irvine Scientific,
Santa Ana, CA), 5% NCTC 109, 2 mM glutamine, 5 
 
3
 
 10
 
2
 
5
 
 M
2-ME, and antibiotics.
 
Antibodies and Reagents.
 
The following mAbs were used for
purifying CD8
 
1
 
 2C or CD8
 
2
 
 2C cells and were described previ-
ously (19): 3.168 (anti-CD8), RL172 (anti-CD4), J11d (anti–heat
stable antigen), 28-16-8s (anti–I-A
 
b
 
). The hybridoma producing
1B2 mAb (clonotypic anti-2C TCR) was provided by Dr. H.
Eisen (Massachusetts Institute of Technology, Cambridge, MA).
FITC-conjugated 1B2 mAb or biotin-conjugated 1B2 mAb were
prepared as previously described. FITC-conjugated anti-CD25,
anti-CD69, and PE-conjugated anti-CD8 were purchased from
PharMingen (San Diego, CA). Cytochalasin D, cycloheximide,
colchicine, and genistein were purchased from Calbiochem Corp.
(La Jolla, CA).
 
Peptides.
 
The peptides used (Table 1) were synthesized on a
synthesizer (431 A; Applied Biosystems, Foster City, CA), and
were purified with C18 reverse-phase HPLC at the peptide labo-
ratory of R.W. Johnson Pharmaceutical Research Institute (La
Jolla, CA). Concentrations of peptides were determined by quan-
titative amino acid analysis.
 
Drosophila cell APCs. Drosophila
 
 APCs were constructed by
transfecting Schneider SC2 cells with cDNA for L
 
d
 
, 
 
b
 
2-micro-
globulin, B7-1, and/or ICAM-1 as described previously (20, 21).
The stable cell lines were selected and maintained by culturing the
cell lines in the presence of 500 
 
m
 
g/ml geneticin (GIBCO BRL)
in culture medium at room temperature (25
 
8
 
C). The genes used
for transfection had a metallothionein promoter, and expression
of the genes was induced by addition of CuSO
 
4
 
 to a final concen-
tration of 1 mM. For use as APCs, cells cultured with CuSO
 
4
 
 for
24 h were washed three times in HBSS solution containing 2.5%
horse serum, and preincubated for 2 h with or without peptides.
 
Purification of CD8
 
1
 
 and CD8
 
2
 
 2C Cells.
 
For cell purification
(19), 2C LN cells were first treated with a cocktail of mAbs (anti-
CD4, anti-HSA, anti–I-A
 
b
 
) plus C for 45 min at 37
 
8
 
C. The sur-
viving cells were further separated into CD8
 
1
 
 and CD8
 
2
 
 (CD4
 
2
 
)
cells by panning at 4
 
8
 
C for 60–90 min on petri dishes coated with
anti-CD8 mAb; nearly all of these cells had a naive (CD44
 
lo
 
) phe-
notype (22). Nonattached cells were eluted and treated with anti-
CD8 and C to obtain CD8
 
2
 
1B2
 
1
 
 2C cells. The attached CD8
 
1
 
1B2
 
1
 
 2C cells were recovered by incubation at 37
 
8
 
C for 5 min
followed by vigorous pipetting.
 
Proliferation Assay.
 
Purified populations of CD8
 
1
 
 or CD8
 
2
 
2C cells were cultured with irradiated stimulator cells in 200 
 
m
 
l wells
(19). B10.D2 spleen cells were exposed to 2,000 cGy, washed,
incubated at 5 
 
3
 
 10
 
6
 
 cells per ml with or without the indicated
peptides at 25
 
8
 
C for 2 h, and then plated out without washing.
Responder cells were used at 2.5 
 
3
 
 10
 
4
 
 per well and stimulators
were used at 5 
 
3
 
 10
 
5
 
 per well. To measure T cell proliferation,
cultures were pulsed with 1 
 
m
 
Ci of [
 
3
 
H]thymidine 8 h before
harvest. The data in the figures refer to the mean of triplicate cul-
tures; standard deviations were generally within 5–15% of the
mean.
 
Flow Cytometric Analysis of Surface and Intracellular Molecules.
 
CD8
 
1
 
 or CD8
 
2
 
 2C cells (0.5 
 
3
 
 10
 
6
 
) were cultured with T-depleted
spleen cells (5 
 
3
 
 10
 
6
 
) or 
 
Drosophila
 
 APCs (1 
 
3
 
 10
 
6
 
) in the pres-
ence or absence of peptides for the indicated time. The cells were
washed once with 3 ml of ice-cold PBS containing 2.5% horse se-
rum and 0.2% sodium azide. For TCR surface staining, cells were
incubated with PE-conjugated anti-CD8 mAb and FITC-conju-
gated 1B2 mAb. For CD25 and CD69 surface staining, cells were
incubated with PE-conjugated anti-CD8 mAb plus FITC-conju-
gated anti-CD25 or FITC-conjugated anti-CD69 mAbs. Propi-
dium iodide was included during staining at a concentration of
1 
 
m
 
g/ml. Live cells (propidium iodide negative) were acquired
and analyzed on a FACScan
 
Ò
 
 (Becton Dickinson, San Jose, CA).
For surface versus cytoplasmic staining of TCR and CD3, cells
were first incubated with red 613–conjugated anti-CD8 plus bi-
otin-conjugated 1B2 mAb or biotin-conjugated anti-CD3 mAb,
followed by incubation with PE-conjugated streptavidin. After
incubation with unconjugated 1B2 or anti-CD3 mAb (to block
unbound sites), the cells were then fixed with 1% paraformalde-
hyde in PBS containing 0.1% glutaraldehyde and 0.02% Tween
20. The fixed cells were washed and stained with FITC-conju-
gated 1B2 mAb or anti-CD3 mAb. Cells were analyzed on a
FACScan
 
Ò
 
 and the surface and cytoplasmic expression of TCR
and CD3 were examined by gating on CD8
 
1
 
 T cells.
 
Results
 
Experimental Approach.
 
TCR downregulation on T cells
from the 2C line of TCR transgenic mice (18) was exam-
ined with the aid of three peptides recognized by the 2C
TCR in association with L
 
d
 
 MHC class I molecules. The
specificity of 2C cells for L
 
d
 
-associated peptides is summa-
rized below.
The clonotype-positive (1B2
 
1
 
) CD8
 
1
 
 cells in 2C mice
undergo positive selection to K
 
b
 
 (H-2
 
b
 
) molecules and dis-
play strong alloreactivity to endogenous peptides bound to
L
 
d
 
 (H-2
 
d
 
) molecules (18, 23, 24). Based on studies with
peptides eluted from cell surface L
 
d
 
 molecules, the alloreac-
tivity of 2C T cells appears to be directed predominantly to
an 8-mer peptide, p2Ca, derived from the Krebs cycle en-
zyme, 2 oxoglutarate dehydrogenase (25); p2Ca peptide has
intermediate affinity for soluble L
 
d
 
 molecules and, when
complexed to L
 
d
 
, has high affinity for the 2C TCR (Table
1). 2C T cells display stronger reactivity to a 9-mer variant
of p2Ca termed QL9 (26). Except for one additional amino
acid, QL9 has the same sequence as p2Ca and forms part of
 
Table 1.
 
Features of the Interaction of 2C TCR with L
 
d
 
 and
Self Peptides
 
Peptides Sequence
Binding affinities (M
 
2
 
1
 
) (K
 
a
 
)
Affinity for L
 
d
 
Affinity of 2C TCR
for peptide-L
 
d
 
p2Ca LSPFPFDL 4 
 
3
 
 10
 
6
 
2 
 
3
 
 10
 
6
 
QL9 QLSPFPFDL 2 
 
3
 
 10
 
8
 
2 
 
3
 
 10
 
7
 
SL9 SPFPFDLLL 4 
 
3
 
 10
 
7
 
11.2 
 
3
 
 10
 
4
 
P1A.35-43 LPYLGWLVF 4 
 
3
 
 10
 
9
 
ND
The data on peptide sequences (p2Ca, QL9, and SL9) and the affinity
measurements for L
 
d
 
 are taken from Sykulev et al., (26, 48). Affinity
measurements for 2C TCR binding to soluble peptide/L
 
d
 
 complexes
are based on studies with cell-bound TCR. The affinity of soluble 2C
TCR to L
 
d
 
/p2Ca by BIAcore measurement is 10
 
2
 
7
 
 M (50). The se-
quence of P1A.35-43 peptide is taken from Van den Eynde et al., (27);
the affinity of this peptide for L
 
d
 
 was measured by the current authors
using methods described previously (26, 48). 
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the natural sequence of 2 oxoglutarate dehydrogenase. QL9
peptide has very high binding affinity for both L
 
d
 
 and 2C
TCR molecules, i.e., 50-fold (L
 
d) and 10-fold (TCR) higher
than for p2Ca. The 2C TCR also has specificity for a
weaker peptide, SL9 (Table 1). A control peptide, P1A.35-
43 (27), has no detectable specificity for the 2C TCR but
has high affinity for Ld molecules (Table 1).
When used in high doses, the three peptides recognized
by the 2C TCR are all immunogenic for naive 2C CD81
cells in the absence of added cytokines, and elicit strong
proliferative responses, cytokine production, and effector
cell generation when presented by Ld-transfected RMA-S
cells as APCs (21); with limiting doses of peptide, the im-
munogenicity of QL9 peptide is about 10,000-fold higher
for 2C cells than p2Ca or SL9 peptides. These three pep-
tides are also immunogenic for 2C cells when presented by
artificial APCs, i.e., by Drosophila cells expressing Ld mole-
cules and two costimulatory molecules, B7-1 and ICAM-1
(21, and unpublished data of the authors).
In the case of normal spleen cells as APCs, 2C CD81
cells give strong, but brief, proliferative responses and low
IL-2 production to B10.D2 (Ld) spleen cells in the absence
of exogenous peptides (19, 22); in this situation, the re-
sponse is directed to Ld plus endogenous p2Ca peptide.
Supplementing B10.D2 spleen cells (or purified dendritic
cells) with exogenous p2Ca or QL9 peptide augments the
proliferative response of 2C cells and intensifies IL-2 pro-
duction, thereby prolonging the proliferative response (22).
TCR expression on 2C CD81 cells responding to B10.D2
spleen cells 6 exogenous peptides is discussed below.
Spleen Cells as APCs. To examine TCR expression, pu-
rified populations of naive phenotype (CD44lo) CD81 cells
were prepared from 2C LN and cultured in vitro with Ld-
positive B10.D2 spleen cells or Ld-negative H-2 recombi-
nant R103 (KdDbL2) spleen cells 6 peptides for up to 3 d.
The cells were then harvested, stained for the clonotypic 2C
TCR (1B2), for CD69 and CD8 expression, and FACSÒ
analyzed. The data in Fig. 1 show TCR and CD69 expres-
sion on gated CD81 cells for cultures harvested after vari-
ous periods. The data make two points.
First, relative to T cells cultured in medium alone or
held at 48C or cultured with nonstimulating Ld-negative
R103 spleen, no detectable TCR downregulation oc-
curred when 2C cells were cultured with B10.D2 spleen
cells in the absence of exogenous peptide (Fig. 1, A, B a,
and B b). The failure to detect TCR downregulation ap-
plied at all time points measured between 30 min and 66 h
of culture (Fig. 1, A and B). Despite the lack of TCR
downregulation, contact of 2C cells with endogenous p2Ca
peptide on B10.D2 spleen cells caused maximal upregula-
tion of CD69 (Fig. 1, B c and C) and a strong T prolifera-
tive response (see below). These data suggest that for 2C
cells, TCR downregulation detectable via FACSÒ analysis
is not a prerequisite for T cell activation.
Second, culturing 2C T cells with B10.D2 spleen sup-
plemented with the strong QL9 peptide (1025 M, 10 mM)
accelerated the onset of high CD69 expression (relative to
B10.D2 spleen without added peptide; Fig. 1 B c), but
caused near-complete TCR downregulation (Fig. 1, A, B,
and C). TCR downregulation was maximal at 6 h and re-
mained low for 12 h (Fig. 1, A, B a, B b, and data not
shown). Thereafter, TCR expression gradually increased
(despite continuous exposure to APCs plus peptide) and
reached normal levels by 66 h (Fig. 1 A). With the two
weaker peptides, p2Ca and SL9, TCR downregulation was
undetectable with SL9 (Fig. 1 C) and partial with p2Ca (see
below); no TCR downregulation was seen with the con-
trol P1A peptide (Fig. 1 B a). These data applied to high
concentrations of peptides (1025 M) and with B10.D2
spleen as APCs. In marked contrast to B10.D2 spleen, add-
ing the strong QL9 peptide to nonstimulatory Ld-negative
Figure 1. TCR and CD69 expression on CD81 2C cells stimulated by
spleen cells in the absence or presence of peptides. 5 3 105 CD81 2C
cells were cultured with 5 3 106 T-depleted B10.D2 (Ld1) or R103 (Ld2)
spleen cells in the presence or absence of p2Ca, QL9, SL9, or P1A pep-
tides (10 mM) for the indicated time (12 h for C). The cells were har-
vested and stained with PE-conjugated anti-CD8 mAb and FITC-conju-
gated 1B2 mAb. TCR expression was analyzed by FACScanÒ gating on
CD81 2C cells. In B, the mean fluorescence intensity (MFI) of staining is
shown. The data in A, B a, B b, B c, and C are from five separate experi-
ments.644 Requirements for TCR Downregulation
R103 spleen failed to cause TCR downregulation or up-
regulation of CD69 (Fig. 1, B b and B c).
TCR Downregulation Reflects Internalization. To exclude
the possibility that TCR downregulation reflected shed-
ding from the cell surface, 2C T cells were stimulated with
B10.D2 spleen 6 peptides (1025 M) for 12 h. Using two-
color staining, the cells were surface stained for TCR or
CD3, permeabilized by fixation, and then stained for TCR
and CD3 (CD3e) internally. As shown in Fig. 2, 2C cells
cultured with B10.D2 spleen without added peptide or
with SL9 peptide showed high levels of surface (s)1 TCR
and CD3, but only low levels of internal (i) TCR and
CD3; similar findings applied when QL9 peptide was
added to Ld-negative R103 spleen. With B10.D2 spleen
plus QL9 peptide, however, the disappearance of sTCR
and sCD3 was associated with a marked increase in iTCR
and iCD3. These findings indicate that TCR and CD3 down-
regulation reflected internalization rather than shedding.
Influence of CD8 Expression on TCR Downregulation. CD8
molecules function by augmenting TCR contact with pep-
tide/MHC class I complexes on APCs and also by promot-
ing intracellular signaling via association with p56lck (28,
29). In the absence of CD8 function, e.g., when anti-CD8
mAb is added to culture, the proliferative response of naive
2C CD81 cells to B10.D2 spleen without added peptides is
undetectable unless the cells are supplemented with exoge-
nous cytokines (19); similar findings apply when the CD82
(CD4282) subset of 2C cells are used as responders. With
addition of the strong QL9 peptide to B10.D2 spleen cells,
however, CD8 function becomes redundant, implying that
CD8 function is only required when the avidity of T/APC
interaction is low (22). This is illustrated in Fig. 3 A where
it can be seen that the clonotype-positive (1B21) subset of
CD82 2C cells failed to proliferate in response to B10.D2
spleen cells without exogenous peptide but gave high re-
sponses to B10.D2 spleen supplemented with QL9 peptide
(bottom). CD81 2C cells, by contrast, responded strongly to
B10.D2 spleen in the absence of added peptide (top). As
discussed elsewhere, CD81 2C cells behave identically to
CD82 2C cells when supplemented with anti-CD8 mAb
(19), implying that the CD82 subset is not innately pecu-
liar.
The above findings indicate that CD8 is an important
coreceptor for T cell activation, but is not needed when
the avidity of T/APC interaction is high, e.g., when APCs
express the high affinity QL9 peptide. This poses the ques-
tion of whether CD8 expression plays a role in TCR down-
regulation. This issue was addressed by culturing CD81 ver-
sus CD82 2C cells with B10.D2 spleen cells supplemented
with graded concentrations of QL9 versus p2Ca peptides. As
shown in Fig. 3 B, the susceptibility of these two subsets of
2C cells to TCR downregulation was indistinguishable. With
QL9 peptide, maximal TCR downregulation at 12 h was
seen with 1028 M peptide. TCR downregulation failed to
impair T cell function because both CD81 and CD82 2C
cells gave strong proliferative responses to B10.D2 spleen
plus QL9 peptide at 1027–1028 M (Fig. 3 A), i.e., at pep-
tide concentrations causing complete TCR downregulation.
For the weaker p2Ca peptide, adding this peptide to ei-
ther CD81 or CD82 2C cells at low concentrations caused a
paradoxical mild enhancement of TCR expression (Fig. 3 B).
At higher concentrations, p2Ca peptide induced TCR down-
regulation. At the highest concentration tested (1025 M),
TCR downregulation by p2Ca peptide was incomplete
and equivalent to the partial TCR downregulation induced
by a 10,000-fold lower dose of QL9 peptide (1029 M). As
discussed earlier (Figs. 1 and 2), the third immunogenic pep-
tide, SL9, failed to cause TCR downregulation at .1025 M.
The above findings indicate that TCR downregulation is
(a) peptide dose dependent, (b) most prominent with high-
affinity peptides, (c) independent of CD8 expression, and
(d) apparently unrelated to the subsequent functional re-
sponse of T cells. On this last point, it may be noted that
2C cells gave strong proliferative responses irrespective of
whether TCR expression was upregulated (p2Ca peptide
at 1027 M) or completely downregulated (QL9 at 1027 M)
(Fig. 3 and data not shown).
Influence of Costimulatory Molecules. Stimulation of T cells 1Abbreviations used in this paper: CCD, cytochalasin D; i, internal; s, surface.
Figure 2. Surface and cytoplasmic staining of TCR and CD3 on CD81
2C cells exposed to spleen cells 6 peptides. 5 3 105 CD81 2C cells were
cultured with 5 3 106 B10.D2 or R103 spleen cells in the absence or
presence of 10 mM QL9 or SL9 peptides for 12 h. The cells were har-
vested and stained as described in Materials and Methods. The external
and internal expression of TCR and CD3 on the 2C cells were then ana-
lyzed by FACScanÒ gating on CD81 cells.645 Cai et al.
via TCR molecules is generally ineffective unless accompa-
nied by costimulatory signals (30, 31). These “second sig-
nals” are crucial for cytokine production and differentiation
into effector cells. Costimulation is thought to be largely a
reflection of T cell CD28 molecules interacting with B7
(B7-1, B7-2) on APCs (32, 33). Nevertheless, costimula-
tion can also be provided through interactions between
complementary adhesion molecules, e.g., between LFA-1
and ICAM-1 (34–37). Whether this form of costimulation
is due solely to enhanced cell adhesion or is also associated
with the production of unique second signals is unclear (21,
38). The role of B7 and ICAM-1 in TCR downregulation
is discussed below.
In initial experiments, 2C T cells were cultured with
B10.D2 spleen cells plus QL9 peptide (1025 M) in the pres-
ence of CTLA4Ig, a reagent that binds to B7-1 and B7-2
on APCs and thus blocks CD28/B7 interaction (39). Even
at high concentrations, CTLA4Ig had little if any capacity
to prevent TCR downregulation (data not shown). Since
spleen APCs express a spectrum of molecules with poten-
tial costimulatory function, the role of individual costimu-
latory molecules on TCR downregulation was examined
with the aid of a panel of Ld-transfected Drosophila cells as
APCs. These cells expressed Ld alone (Ld APCs), Ld 1 B7-1
(Ld.B7), Ld 1 ICAM-1 (Ld.ICAM), or Ld 1 B7-1 1
ICAM-1 (Ld.B7.ICAM). The capacity of these Drosophila
APCs to elicit proliferative responses of 2C CD81 cells in
the absence of added cytokines is discussed elsewhere (21)
and is summarized in Fig. 4, right. For QL9 peptide, prolif-
erative responses are undetectable with Ld APCs, weak but
detectable with Ld.B7 or Ld.ICAM APCs, and very strong
with Ld.B7.ICAM APCs; for p2Ca peptides, proliferative
responses are seen only with Ld.B7.ICAM APCs.
TCR and CD8 expression on CD81 2C cells exposed to
the panel of Drosophila APCs plus QL9 versus p2Ca peptide
for 12 h are shown in Fig. 4; the peptides were added at
1025 M. For p2Ca peptide, TCR expression was high or
only slightly reduced with each type of Drosophila APC.
With QL9 peptide, by contrast, TCR expression was greatly
reduced, even with Drosophila cells expressing Ld alone.
Therefore, TCR downregulation did not appear to require
costimulation. Similar findings applied to CD3 expression
(data not shown), implying that TCR downregulation did
not simply reflect TCR blockade. In contrast to TCR and
CD3 expression, neither peptide caused a change in CD8
Figure 3. Influence of 2C
CD8 expression on TCR down-
regulation and T cell activation.
(A) Proliferative responses of 2C
cells to B10.D2 spleen APCs 6
QL9 peptide. Purified CD81 or
CD82 2C cells (5 3 104) were
cultured with B10.D2 spleen
cells (5 3 105) in the absence or
presence of titrated concentra-
tions of QL9 peptides for 3 d.
[3H]thymidine (1 mCi) was
added during the last 8 h of cul-
ture. (B) TCR downregulation
on 2C T cells. Purified CD81 or
CD82 2C T cells (5 3 105) were
cultured with T-depleted
B10.D2 spleen cells (5 3 106) in
the absence or presence of a ti-
trated concentration of QL9 or
p2Ca peptides for 12 h. The cells
were harvested and stained for
TCR expression with FITC-
conjugated 1B2 mAb. The ex-
pression of TCR on 2C cells was
analyzed on gated Thy-11 cells.
Figure 4. Influence of costimulation on TCR downregulation and T cell
activation. Purified CD81 2C cells (5 3 105) were incubated with the in-
dicated transfected Drosophila cells (1 3 106) plus p2Ca or QL9 peptides
(10 mM) in bulk (2 ml) culture for 12 h and stained for TCR (1B2) and
CD8 expression. (Top) staining of noncultured 2C cells is shown as a con-
trol. The summarized data on proliferative responses of 2C cells to p2Ca
and QL9 peptides are taken from Cai et al. (21).646 Requirements for TCR Downregulation
expression (Fig. 4). These findings with naive 2C cells also
applied to presensitized T cells, i.e., to 2C cells harvested 3 d
after exposure to Ld.B7.ICAM APCs plus QL9 peptide
(data not shown).
The above data apply to high concentrations of peptides
(1025 M). The effects of using limiting doses of QL9 pep-
tide are shown in Fig. 5. Under these conditions, the ca-
pacity of Ld and Ld.B7 APCs to cause QL9-mediated TCR
downregulation of naive 2C cells was virtually identical, im-
plying that B7-1 expression played no detectable role in TCR
Figure 5. Influence of B7-1
and ICAM-1 expression on pep-
tide-induced 2C TCR down-
regulation. (A) 5 3 105 purified
CD81 2C cells were cultured
with 1 3 106 Drosophila APCs in
the presence of a titrated con-
centration of QL9 peptides for
12 h. The cells were harvested
and stained with FITC-conju-
gated 1B2 or FITC-conjugated
anti-CD69. The data show TCR
and CD69 expression on gated
CD81 2C cells. The data in A
and B are from two separate ex-
periments.
Figure 6. Effects of CCD on TCR downregulation and T cell activation. Purified CD81 2C cells (5 3 105) were cultured with 1 3 106 Drosophila
APCs (top, Ld.B7 cells and bottom Ld.ICAM cells) in the presence of a titrated dose of QL9 peptide for 12 h. CCD was added at the beginning of the cul-
ture at a final concentration of 4 mg/ml. The cells were harvested and stained for FITC-conjugated anti-CD25, FITC-conjugated anti-CD69, or FITC-
conjugated 1B2 (TCR) mAbs. The cells were analyzed on a FACScan and the data show the mean fluorescence intensity (MFI) on gated CD81 2C cells
stained with each mAb. The data in A and B are from different experiments.647 Cai et al.
downregulation. Interestingly, in contrast to B7-1, ICAM-1
expression appeared to potentiate TCR downregulation.
Thus, at limiting doses of peptides (1027–1029 M) TCR
downregulation was more pronounced with ICAM-11
APCs (Ld.ICAM or Ld.B7.ICAM cells) than with ICAM-12
APCs (Ld or Ld.B7 APCs; Fig. 5 A, left). Several other ex-
periments, e.g., Fig. 5 B, gave similar results.
These findings with limiting concentrations of QL9 pep-
tide indicated that TCR downregulation did not require
typical costimulation via B7-1, but was significantly aug-
mented by contact with ICAM-1. Quite different results oc-
curred when the T cells were typed for CD69 expression.
Thus, in the presence of graded concentrations of QL9 pep-
tide, upregulation of CD69 expression on 2C cells was vir-
tually undetectable with Ld APCs, moderate with either
Ld.B7 or Ld.ICAM APCs, and very high with Ld.B7.ICAM
APC (Fig. 5 A, right). The requirements for inducing TCR
downregulation and T cell activation (CD69 upregulation)
thus seemed to be unrelated. Except for a mild effect of
ICAM-1 at low peptide concentrations, TCR downregu-
lation appeared to depend solely on contact with Ld mole-
cules. By contrast, T cell activation was critically dependent
upon costimulation provided either by B7-1 or ICAM-1;
optimal T cell stimulation required the combined expres-
sion of B7-1 and ICAM-1.
Since TCR downregulation was enhanced only by ICAM-1
and not B7-1, it seemed likely that ICAM-1 acted simply
by promoting conjugate formation (cell adhesion), i.e., by
binding to LFA-1 coreceptors on 2C cells and thus facili-
tating TCR contact with Ld 1 peptide on the APCs.
However, the possibility that ICAM-1 initiated unique sig-
naling events that potentiated TCR downregulation could
not be excluded. Since LFA-1 interaction with ICAM-1
involves LFA-1 association with the cytoskeleton (40), cul-
tures were supplemented with cytochalasin D (CCD), a drug
that inhibits actin filament polymerization (41).
The effects of adding CCD to 2C cells cultured with
Ld.B7 versus Ld.ICAM Drosophila APCs plus graded con-
centrations of QL9 peptide are shown in Fig. 6 A. In the
case of TCR expression, CCD had only a very mild effect
in reducing TCR downregulation. This effect was seen in
several different experiments and tended to be slightly
more pronounced for Ld.ICAM than Ld.B7 APCs (see also
Fig. 6 B, right). For CD25 (IL-2Ra) and CD69 expression,
however, the results were much more dramatic (Fig. 6 B).
Thus, with Ld.ICAM APCs, addition of CCD profoundly
reduced upregulation of CD25 and CD69 expression, es-
pecially at low concentrations of peptide. With Ld.B7
APCs, by contrast, CCD failed to impair CD25 or CD69
upregulation; indeed, the upregulation of these markers
was slightly increased in the presence of CCD. The impli-
cations of these findings will be discussed later.
Metabolic Requirements for TCR Downregulation. The ca-
pacity of various metabolic inhibitors to impair TCR
downregulation was measured with B10.D2 spleen cells as
APCs 6 QL9 peptide (1025 M); drugs were dissolved in
DMSO and TCR expression on CD81 2C cells was exam-
ined at 12 h. As shown in Fig. 7, relatively high concentra-
tions of cycloheximide (100 mg/ml, inhibitor of protein
synthesis), colchicine (20 mg/ml, inhibitor of microtubule
polymerization; 42), CCD (see above), genistein (200 mM,
inhibitor of tyrosine-specific protein kinase; 43) or sodium
azide (0.2%, cytochrome oxidase inhibitor) had no detect-
able effect in inhibiting TCR downregulation at the time
point studied. However, with the exception of colchicine,
each drug prevented CD69 upregulation (though in accor-
dance with the data in Fig. 6, the inhibition induced by
CCD was prominent only when the B10.D2 APCs were
not supplemented with QL9 peptide). Higher concentra-
tions of drugs, e.g., 1% sodium azide, did reduce TCR
downregulation, but substantially impaired cell viability,
implying that the effects were nonspecific. The only ap-
proach tested that prevented TCR downregulation with-
out causing cell damage was to culture cells at 48C (Fig. 7 B).
Figure 7. Metabolic requirements for TCR downregulation. CD81
2C cells (1 3 106) were cultured with 5 3 106 CD8-depleted B10.D2
spleen cells in the presence or absence of 10 mM QL9 peptides for 12 h.
Inhibitors were added at the beginning of the cultures as indicated. Cells
were harvested and stained for the expression of TCR (1B2) and CD69 as
described in Materials and Methods. Staining for TCR and CD69 expres-
sion is shown in the form of histograms (A) and MFI (B) and was ob-
tained by gating on CD81 cells. In A, the histograms at the bottom refer
to staining of control 2C cells cultured at 48C in the absence of APCs. In
B, the inhibitors were added at 200 mM for genistein, 4 mg/ml for CCD,
and 0.2% for sodium azide.648 Requirements for TCR Downregulation
Discussion
Under physiological conditions, TCR binding to pep-
tide/MHC complexes on APCs elicits T cell activation via
an intracellular signaling cascade involving a series of phos-
phorylation-driven events (44). However, TCR-mediated
signaling is generally abortive unless amplified by co-recog-
nition of MHC molecules by CD4 or CD8 molecules and
accompanied by the delivery of “second signals” through
recognition of costimulatory molecules, e.g., B7, on APCs
(2, 30). The precise requirements for inducing signal trans-
duction via TCR/CD3 molecules is unclear (44). The
prevailing view is that signaling reflects TCR/CD3 cross-
linking which leads to conformational changes in these
molecules and activation of intracellular protein tyrosine
kinases such as p56lck and fyn. As mentioned earlier (see In-
troduction), an alternative possibility is that T cell activa-
tion is not initiated by TCR/CD3 cross-linking per se, but
by internalization of these components (17). A key ques-
tion here is whether such TCR downregulation is an es-
sential prelude to signaling or merely an epiphenomenon.
In this paper we compared the requirements for induc-
ing TCR downregulation versus T cell activation. This
question was addressed with the aid of a well-characterized
system in which a monoclonal population of naive T cells
was exposed to specific peptides presented by APCs bear-
ing defined costimulatory molecules. The results show that
the requirements for inducing TCR downregulation and
T cell activation show little or no correlation. Confirming
previous findings (21), the activation of 2C T cells leading
to CD69 upregulation, CD25 expression, and cell division
required costimulation via B7 or ICAM-1. Except with the
high affinity QL9 peptide, 2C activation was also depen-
dent upon the coreceptor function of CD8. These require-
ments did not apply to TCR downregulation. Thus, with
QL9 peptide, induction of TCR downregulation on 2C
cells appeared to depend simply upon peptide/MHC inter-
action and was not influenced by either CD8 or B7 expres-
sion. With regard to B7, in other experiments we observed
QL9-mediated TCR downregulation of 2C cells with a
number of B72 ICAM-12/lo cell lines (P815 cells, Ld-trans-
fected fibroblasts, Ld-transfected RMA-S cells) and also
with 5m Dynabeads coupled with QL9/Ld complexes (au-
thors and A. Luxemberg, unpublished data). Induction of
TCR downregulation in the absence of costimulation was
thus not unique to Ld Drosophila cells.
TCR downregulation was clearly not sufficient for T cell
activation because exposure to QL9 peptide on Drosophila
cells expressing Ld alone caused marked TCR downregula-
tion, but only minimal signs of T cell activation (limited to
a slight increase in CD69 expression with high doses of
peptide). Conversely, TCR downregulation did not seem
to be mandatory for T cell activation because culturing 2C
cells with B10.D2 spleen without exogenous peptide stim-
ulated a strong proliferative response but failed to cause de-
tectable TCR downregulation. This finding should be
viewed with caution, however, because FACSÒ analysis
may not be sufficient to detect a minor degree of TCR
downregulation. Thus, Viola and Lanzavecchia (16) argue
that T cell activation requires downregulation of only a
small proportion of total TCR molecules, i.e., z8,000
molecules per cell with B72 APCs and 1,500 molecules per
cell with B71 APCs. Although it is difficult to definitively
rule out this level of TCR downregulation, it is notable
that adding limiting doses of the weaker p2Ca peptide to
B10.D2 spleen potentiated the proliferative response (22),
but caused a paradoxical increase rather that a decrease in
TCR expression (Fig. 3). These findings are difficult to
reconcile with the notion that TCR downregulation is a
prerequisite for T cell activation. Nevertheless definitive
information on this question will require the use of more
sensitive methods for quantitating TCR levels. At present,
the possibility that the cells downregulated a very small but
significant number of TCR molecules cannot be excluded.
Although TCR downregulation was not influenced by
B7 expression, it is of interest that, with Drosophila cells as
APCs, TCR downregulation was slightly enhanced by
Ld.ICAM cells relative to either Ld or Ld.B7 cells. The sim-
plest explanation for these data is that TCR downregula-
tion does not require classic costimulation but is facilitated
by the enhanced conjugate formation induced by the adhe-
sive function of LFA-1/ICAM-1 interaction. It is impor-
tant to stress, however, that the role of ICAM-1 in aug-
menting TCR downregulation was quite mild and was
only seen with limiting doses of peptides. This contrasted
with the requirements for T cell activation where ICAM-1
had a decisive influence. Thus, induction of CD69 expres-
sion was barely detectable with Ld APCs, but was quite
strong with Ld.ICAM APCs, in fact, as strong as with Ld.B7
APCs. ICAM-1 thus seemed to play only a minor role in
TCR downregulation, but had a major influence on T cell
activation. This difference implies that the role of LFA-1/
ICAM-1 interactions in TCR downregulation and T cell
activation is distinctly different. How can this be explained?
Although the interaction between LFA-1 and ICAM-1
is known to augment cell adhesion (45), this interaction is
also reported to provide costimulatory or “coactivation”
function (34–37), implying that LFA-1/ICAM-1 interac-
tion can be bifunctional. During the initial interaction be-
tween T cells and APCs, LFA-1/ICAM-1 interaction prob-
ably acts primarily by enhancing cell adhesion, thus facilitating
contact with APCs expressing limiting concentrations of
peptide. The present results with CCD could be viewed as
supporting the concept that the adhesive function of LFA-1
is not constitutive on resting T cells (34, 45), but requires
association with the cytoskeleton, presumably as the result
of earlier TCR ligation. This may be an overinterpretation
of the data, however, because the effects of CCD in pre-
venting TCR downregulation were minor and were only
marginally greater for Ld.ICAM than for Ld.B7 APCs.
After initial T/APC interaction, one can envisage that
the adhesive function of LFA-1/ICAM-1 interaction con-
tinues, but that LFA-1 now assumes a role as a costimula-
tory molecule. As documented here and elsewhere (21),649 Cai et al.
ICAM-1 and B7 each act as quite potent costimulatory
molecules when expressed on Drosophila APCs. It is nota-
ble, however, that CCD markedly impaired the costimula-
tory function of ICAM-1, but had little effect on the role
of B7. This finding raises the possibility that ICAM-1 and
B7 use different signaling pathways for costimulation,
which could explain the marked synergism observed when
these two molecules are coexpressed on APCs (21, 38).
Though minor, the role of LFA-1/ICAM-1 interaction
in TCR downregulation was clearly detectable. This con-
trasted with CD8 expression where TCR downregulation
on 2C cells was as marked with CD82 cells as with CD81
cells over a wide range of peptide concentrations. The
apparent CD8 independence of TCR downregulation might
seem surprising since CD8 interaction with class I is thought
to play a significant role in augmenting TCR/peptide/class
I interaction (29, 46). For 2C cells, CD8 expression is
clearly important for T cell activation to p2Ca and related
peptides, especially with limiting concentrations of peptide
(19, 22, 47, Fig. 3). This may not be the case for initial
TCR/peptide/class I interaction, however, because the
binding of soluble p2Ca/Ld complexes to intact CD81 2C
cells cannot be inhibited with anti-CD8 mAb (48). There-
fore, the implication is that for the interaction of cell-
bound 2C TCR molecules with the high affinity p2Ca and
QL9 peptides, CD8 acts solely as a triggering molecule,
presumably by focusing p56lck in the vicinity of the TCR/
CD3 complex (26). This function is crucial for cell activa-
tion, but not for TCR downregulation.
Collectively, the data on ICAM-1, B7, and CD8 expres-
sion suggest that these molecules play a crucial role in T cell
triggering, but only a minor or undetectable role in TCR
downregulation. What, then, are the requirements for in-
ducing TCR downregulation? According to others, TCR
downregulation is an active process requiring tyrosine and/
or serine phosphorylation of intracellular proteins after acti-
vation of protein kinase C (for review see reference 11).
However, these studies involved exposing T cells to phor-
bol esters and/or the use of T cell clones, and did not ex-
clude secondary effects mediated by contaminating APCs.
Hence it is unclear whether protein phosphorylation is es-
sential for TCR downregulation at the level of naive T cells.
In this respect, it is notable that the tyrosine kinase inhibi-
tor, genistein, was fully effective in blocking 2C T cell acti-
vation (CD69 upregulation), but failed to impair TCR down-
regulation even at relatively high concentrations (200 mM)
(Fig. 7). Several other metabolic inhibitors including so-
dium azide and cycloheximide had similar effects. It is
therefore conceivable that TCR downregulation simply re-
flects a conformational change in TCR (and/or CD3) com-
ponents which targets these molecules for endocytosis via
clathrin-coated pits. Whatever the explanation, TCR down-
regulation seems to be neither sufficient nor essential for
cell activation. We favor the view that TCR downregula-
tion is a byproduct of strong TCR ligation. Since TCR
downregulation is most prominent with high affinity pep-
tides, internalization of the TCR could be a protective
measure to guard against the negative effects of excessive
T cell triggering. In favor of this idea, recent evidence of
Valitutti et al. suggests that TCR downregulation can lead
to “extinction of signaling” (49).
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